Dynamic changes of serum sICAM-1 and sFlt-1 in patients with skull base tumors after surgery and their relationship with cerebral vasospasm
Wang Ke,Bao Zhijun,Liang Yanbin,Yang Zhibo,Zhang Jun
DOI: https://doi.org/10.3969/j.issn.1671-6450.2023.05.005
2023-01-01
Abstract:Objective To analyze the dynamic changes of serum soluble intercellular adhesion molecule-1（sICAM-1） and soluble Fms-like tyrosine kinase 1（sFlt-1） in patients with skull base tumors after surgery and their correlation with postoperative cerebral vasospasm（CVS）. Methods From April 2021 to August 2022, 123 patients with skull base tumors admitted to the Second Department of Neurosurgery of 321 Hospital were selected as the observation group. According to whether the patients developed CVS after surgery, they were divided into a subgroup of 71 patients without CVS and a subgroup of 52 patients with CVS. According to different degrees of CVS, the patients with CVS were divided into a mild subgroup of 22 cases, a moderate subgroup of 17 cases, and a severe subgroup of 13 cases. In addition, 120 health examination personnel from hospitals in the same period were selected as the health control group. Serum levels of sICAM-1 and sFlt-1 were measured in subjects. The diagnostic value of serum sICAM-1 and sFlt-1 on postoperative CVS in patients with skull base tumors was analyzed using the subject operating characteristic curve（ROC） 3 days after surgery. Results Compared with the healthy control group, the serum levels of sICAM-1 and sFlt-1 in the observation group significantly increased before and on the 3rd, 7th, and 14th days after surgery（F/P=1 583.113/＜0.001, 849.906/＜0.001）; Compared with pre operation, the serum levels of sICAM-1 and sFlt-1 in the observation group significantly increased on the 3rd, 7th, and 14th days after operation（F/P=1 256.460/＜0.001, 463.461/＜0.001）, and reached the highest value on the 7th day after operation; Compared with 7 days after surgery, the serum levels of sICAM-1 and sFlt-1 in the observation group were significantly lower on 14 days after surgery（P＜0.05）. Compared with the non-CVS subgroup, the levels of sICAM-1 and sFlt-1 in the patients with CVS subgroup significantly increased 3 days after surgery（t/P=11.688/＜0.001, 6.887/＜0.001）, and the levels of sICAM-1 and sFlt-1 in the mild, moderate, and severe subgroups increased sequentially（F/P=18.820/＜0.001, 29.845/＜0.001）; The ROC curve showed that the area under curve（AUC） of serum sICAM-1, sFlt-1, and their combination in the diagnosis of postoperative CVS in skull base tumors were 0.842, 0.821, and 0.924, respectively. The combined diagnostic efficacy of the two tests was higher than that of the single test（Z/P=2.029/0.042, 2.235/0.025）. Conclusion The serum levels of sICAM-1 and sFlt-1 in patients with skull base tumors showed an upward trend before surgery and on the 3rd and 7th days after surgery, but decreased on the 14th day after surgery, which is related to the occurrence of CVS after surgery, and has certain diagnostic value for the occurrence of CVS after surgery for skull base tumors.